Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease Donohue JF; Jones PWInt J Chron Obstruct Pulmon Dis 2011[Jan]; 6 (ä): 35-45Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Developments in the understanding of COPD have led to standard guidelines for diagnosis, treatment, and spirometry assessments, which have in turn influenced trial designs and inclusion criteria. Substantial clinical evidence has been gained from clinical trials and supports a positive approach to COPD management. However, there appear to be changing trends in recent trials. Large bronchodilator studies have reported lower improvements in trough forced expiratory volume in 1 second (FEV(1)) values versus placebo than were observed in earlier studies, while the rate of FEV(1) decline seems to be lower in more recent trials. In addition, recent evidence has called into question the usefulness of bronchodilator reversibility testing as a trial inclusion criterion. Baseline patient populations and use of concomitant medications have also changed over recent years due to increased treatment options. The impact of these many variables on clinical trial results is explored, with a particular focus on changes in inclusion criteria and patient baseline demographics.|Aged[MESH]|Bronchodilator Agents/*therapeutic use[MESH]|Clinical Trials as Topic/*trends[MESH]|Evidence-Based Medicine/trends[MESH]|Forced Expiratory Volume[MESH]|Humans[MESH]|Lung/*drug effects/physiopathology[MESH]|Middle Aged[MESH]|Patient Selection[MESH]|Pulmonary Disease, Chronic Obstructive/diagnosis/*drug therapy/physiopathology[MESH]|Respiratory Function Tests[MESH]|Time Factors[MESH]|Treatment Outcome[MESH] |